Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Large Drop in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totalling 62,900 shares, a drop of 52.7% from the November 30th total of 132,900 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average daily volume of 211,300 shares, the days-to-cover ratio is presently 0.3 days.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets lowered their price objective on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating for the company in a research report on Monday, December 16th.

Alzamend Neuro Price Performance

NASDAQ ALZN opened at $1.20 on Friday. The business’s 50 day moving average price is $1.37 and its 200-day moving average price is $2.39. Alzamend Neuro has a fifty-two week low of $1.06 and a fifty-two week high of $15.06.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.